Erlotinib 150 mg daily plus chemotherapy in advanced pancreatic cancer: an interim safety analysis of a multicenter, randomized, cross-over phase III trial of the "Arbeitsgemeinschaft Internistische Onkologie"
To date, only limited toxicity data are available for the combination of erlotinib with either capecitabine or gemcitabine as front-line therapy for advanced pancreatic cancer. Within a randomized phase III trial, 281 treatment-naive patients were randomly assigned between capecitabine (2000 mg/m2/d...
Gespeichert in:
| Hauptverfasser: | , , , , , , , , , , , , , , , |
|---|---|
| Dokumenttyp: | Article (Journal) |
| Sprache: | Englisch |
| Veröffentlicht: |
2010
|
| In: |
Anti-cancer drugs
Year: 2010, Jahrgang: 21, Heft: 1, Pages: 94-100 |
| ISSN: | 1473-5741 |
| DOI: | 10.1097/CAD.0b013e32833123ed |
| Online-Zugang: | Verlag, lizenzpflichtig, Volltext: https://doi.org/10.1097/CAD.0b013e32833123ed Verlag, lizenzpflichtig, Volltext: https://journals.lww.com/anti-cancerdrugs/Fulltext/2010/01000/Erlotinib_150_mg_daily_plus_chemotherapy_in.10.aspx 
|
| Verfasserangaben: | Stefan Boeck, Ursula Vehling-Kaiser, Dirk Waldschmidt, Erika Kettner, Angela Märten, Cornelia Winkelmann, Stefan Klein, Georgi Kojouharoff, Thomas Gauler, Ludwig Fischer von Weikersthal, Michael R. Clemens, Michael Geissler, Tim F. Greten, Susanna Hegewisch-Becker, Sascha Neugebauer and Volker Heinemann |
MARC
| LEADER | 00000caa a2200000 c 4500 | ||
|---|---|---|---|
| 001 | 1832495221 | ||
| 003 | DE-627 | ||
| 005 | 20230710161511.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 230126s2010 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1097/CAD.0b013e32833123ed |2 doi | |
| 035 | |a (DE-627)1832495221 | ||
| 035 | |a (DE-599)KXP1832495221 | ||
| 035 | |a (OCoLC)1389822152 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rda | ||
| 041 | |a eng | ||
| 084 | |a 33 |2 sdnb | ||
| 100 | 1 | |a Böck, Stefan |d 1977- |e VerfasserIn |0 (DE-588)129950580 |0 (DE-627)484977768 |0 (DE-576)297917978 |4 aut | |
| 245 | 1 | 0 | |a Erlotinib 150 mg daily plus chemotherapy in advanced pancreatic cancer |b an interim safety analysis of a multicenter, randomized, cross-over phase III trial of the "Arbeitsgemeinschaft Internistische Onkologie" |c Stefan Boeck, Ursula Vehling-Kaiser, Dirk Waldschmidt, Erika Kettner, Angela Märten, Cornelia Winkelmann, Stefan Klein, Georgi Kojouharoff, Thomas Gauler, Ludwig Fischer von Weikersthal, Michael R. Clemens, Michael Geissler, Tim F. Greten, Susanna Hegewisch-Becker, Sascha Neugebauer and Volker Heinemann |
| 264 | 1 | |c 2010 | |
| 300 | |a 7 | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Gesehen am 26.01.2023 | ||
| 520 | |a To date, only limited toxicity data are available for the combination of erlotinib with either capecitabine or gemcitabine as front-line therapy for advanced pancreatic cancer. Within a randomized phase III trial, 281 treatment-naive patients were randomly assigned between capecitabine (2000 mg/m2/day, for 14 days, once every 3 weeks) plus erlotinib (150 mg/day, arm A) and gemcitabine (1000 mg/m2 as a 30-min infusion) plus erlotinib (150 mg/day, arm B). In case of treatment failure, patients were crossed over to a second-line treatment with the comparator cytostatic drug without erlotinib. The primary study endpoint was the time to treatment failure of second-line therapy (TTF2). This interim analysis of toxicity contains safety data from the first 127 randomized patients. During first-line therapy, patients received a median number of three treatment cycles (range 0-13) in both the arms. Regarding chemotherapy, a treatment delay was observed in 12% of the cycles in arm A and in 22% of the cycles in arm B. Dose reductions of the cytostatic drug were performed in 18 and 27% of treatment cycles, respectively. Erlotinib dose reductions were performed in 6 and 11% of all cycles. Grade 3/4 hematological toxicity was <10% in both the arms; major grade 3/4 toxicities in arms A and B were diarrhea (9 vs. 7%), skin rash (4 vs. 12%), and hand-foot syndrome (7 vs. 0%). No treatment-related death was observed. In conclusion, this interim safety analysis suggests that treatment with erlotinib 150 mg/day is feasible in combination with capecitabine or gemcitabine. | ||
| 700 | 1 | |a Vehling-Kaiser, Ursula |e VerfasserIn |4 aut | |
| 700 | 1 | |a Waldschmidt, Dirk |e VerfasserIn |4 aut | |
| 700 | 1 | |a Kettner, Erika |e VerfasserIn |4 aut | |
| 700 | 1 | |a Märten, Angela |d 1968- |e VerfasserIn |0 (DE-588)122240103 |0 (DE-627)081822456 |0 (DE-576)293167931 |4 aut | |
| 700 | 1 | |a Winkelmann, Cornelia |e VerfasserIn |4 aut | |
| 700 | 1 | |a Klein, Stefan |e VerfasserIn |4 aut | |
| 700 | 1 | |a Kojouharoff, Georgi |e VerfasserIn |4 aut | |
| 700 | 1 | |a Gauler, Thomas |e VerfasserIn |4 aut | |
| 700 | 1 | |a Fischer von Weikersthal, Ludwig |e VerfasserIn |4 aut | |
| 700 | 1 | |a Clemens, Michael R. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Geißler, Michael |d 1964- |e VerfasserIn |0 (DE-588)133573222 |0 (DE-627)548763305 |0 (DE-576)299942767 |4 aut | |
| 700 | 1 | |a Greten, Tim F. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Hegewisch-Becker, Susanna |e VerfasserIn |4 aut | |
| 700 | 1 | |a Neugebauer, Sascha |e VerfasserIn |4 aut | |
| 700 | 1 | |a Heinemann, Volker |e VerfasserIn |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Anti-cancer drugs |d Hagerstown, Md. : Lippincott Williams & Wilkins, 1990 |g 21(2010), 1, Seite 94-100 |h Online-Ressource |w (DE-627)320649652 |w (DE-600)2025803-3 |w (DE-576)094502161 |x 1473-5741 |7 nnas |a Erlotinib 150 mg daily plus chemotherapy in advanced pancreatic cancer an interim safety analysis of a multicenter, randomized, cross-over phase III trial of the "Arbeitsgemeinschaft Internistische Onkologie" |
| 773 | 1 | 8 | |g volume:21 |g year:2010 |g number:1 |g pages:94-100 |g extent:7 |a Erlotinib 150 mg daily plus chemotherapy in advanced pancreatic cancer an interim safety analysis of a multicenter, randomized, cross-over phase III trial of the "Arbeitsgemeinschaft Internistische Onkologie" |
| 856 | 4 | 0 | |u https://doi.org/10.1097/CAD.0b013e32833123ed |x Verlag |x Resolving-System |z lizenzpflichtig |3 Volltext |
| 856 | 4 | 0 | |u https://journals.lww.com/anti-cancerdrugs/Fulltext/2010/01000/Erlotinib_150_mg_daily_plus_chemotherapy_in.10.aspx |x Verlag |z lizenzpflichtig |3 Volltext |
| 951 | |a AR | ||
| 992 | |a 20230126 | ||
| 993 | |a Article | ||
| 994 | |a 2010 | ||
| 998 | |g 122240103 |a Märten, Angela |m 122240103:Märten, Angela |d 910000 |d 910200 |e 910000PM122240103 |e 910200PM122240103 |k 0/910000/ |k 1/910000/910200/ |p 5 | ||
| 999 | |a KXP-PPN1832495221 |e 4252155428 | ||
| BIB | |a Y | ||
| SER | |a journal | ||
| JSO | |a {"name":{"displayForm":["Stefan Boeck, Ursula Vehling-Kaiser, Dirk Waldschmidt, Erika Kettner, Angela Märten, Cornelia Winkelmann, Stefan Klein, Georgi Kojouharoff, Thomas Gauler, Ludwig Fischer von Weikersthal, Michael R. Clemens, Michael Geissler, Tim F. Greten, Susanna Hegewisch-Becker, Sascha Neugebauer and Volker Heinemann"]},"id":{"doi":["10.1097/CAD.0b013e32833123ed"],"eki":["1832495221"]},"origin":[{"dateIssuedDisp":"2010","dateIssuedKey":"2010"}],"relHost":[{"origin":[{"dateIssuedDisp":"1990-","publisher":"Lippincott Williams & Wilkins ; Ovid","dateIssuedKey":"1990","publisherPlace":"Hagerstown, Md. ; [Erscheinungsort nicht ermittelbar]"}],"id":{"issn":["1473-5741"],"zdb":["2025803-3"],"eki":["320649652"]},"physDesc":[{"extent":"Online-Ressource"}],"title":[{"title_sort":"Anti-cancer drugs","title":"Anti-cancer drugs"}],"type":{"media":"Online-Ressource","bibl":"periodical"},"note":["Gesehen am 17.10.05"],"disp":"Erlotinib 150 mg daily plus chemotherapy in advanced pancreatic cancer an interim safety analysis of a multicenter, randomized, cross-over phase III trial of the \"Arbeitsgemeinschaft Internistische Onkologie\"Anti-cancer drugs","recId":"320649652","language":["eng"],"pubHistory":["1.1990 -"],"part":{"volume":"21","text":"21(2010), 1, Seite 94-100","extent":"7","year":"2010","issue":"1","pages":"94-100"}}],"physDesc":[{"extent":"7 S."}],"person":[{"given":"Stefan","family":"Böck","role":"aut","display":"Böck, Stefan","roleDisplay":"VerfasserIn"},{"roleDisplay":"VerfasserIn","display":"Vehling-Kaiser, Ursula","role":"aut","family":"Vehling-Kaiser","given":"Ursula"},{"role":"aut","display":"Waldschmidt, Dirk","roleDisplay":"VerfasserIn","given":"Dirk","family":"Waldschmidt"},{"given":"Erika","family":"Kettner","role":"aut","display":"Kettner, Erika","roleDisplay":"VerfasserIn"},{"given":"Angela","family":"Märten","role":"aut","roleDisplay":"VerfasserIn","display":"Märten, Angela"},{"display":"Winkelmann, Cornelia","roleDisplay":"VerfasserIn","role":"aut","family":"Winkelmann","given":"Cornelia"},{"display":"Klein, Stefan","roleDisplay":"VerfasserIn","role":"aut","family":"Klein","given":"Stefan"},{"roleDisplay":"VerfasserIn","display":"Kojouharoff, Georgi","role":"aut","family":"Kojouharoff","given":"Georgi"},{"given":"Thomas","family":"Gauler","role":"aut","roleDisplay":"VerfasserIn","display":"Gauler, Thomas"},{"role":"aut","roleDisplay":"VerfasserIn","display":"Fischer von Weikersthal, Ludwig","given":"Ludwig","family":"Fischer von Weikersthal"},{"role":"aut","display":"Clemens, Michael R.","roleDisplay":"VerfasserIn","given":"Michael R.","family":"Clemens"},{"given":"Michael","family":"Geißler","role":"aut","roleDisplay":"VerfasserIn","display":"Geißler, Michael"},{"roleDisplay":"VerfasserIn","display":"Greten, Tim F.","role":"aut","family":"Greten","given":"Tim F."},{"role":"aut","display":"Hegewisch-Becker, Susanna","roleDisplay":"VerfasserIn","given":"Susanna","family":"Hegewisch-Becker"},{"given":"Sascha","family":"Neugebauer","role":"aut","roleDisplay":"VerfasserIn","display":"Neugebauer, Sascha"},{"role":"aut","roleDisplay":"VerfasserIn","display":"Heinemann, Volker","given":"Volker","family":"Heinemann"}],"title":[{"subtitle":"an interim safety analysis of a multicenter, randomized, cross-over phase III trial of the \"Arbeitsgemeinschaft Internistische Onkologie\"","title":"Erlotinib 150 mg daily plus chemotherapy in advanced pancreatic cancer","title_sort":"Erlotinib 150 mg daily plus chemotherapy in advanced pancreatic cancer"}],"recId":"1832495221","language":["eng"],"type":{"bibl":"article-journal","media":"Online-Ressource"},"note":["Gesehen am 26.01.2023"]} | ||
| SRT | |a BOECKSTEFAERLOTINIB12010 | ||